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Treatment of hemophilia A by gene therapy is adversely affected by inefficient FVIII secretion and the large FVIII gene, which is 
difficult to package in the promising adeno-associated virus (AAV) vectors. Inhibited secretion of FVIII is caused mainly by  
inefficient secretion of its heavy chain. Previously, we have employed a protein splicing-based dual-vector to co-transfer a 
B-domain-deleted FVIII (BDD-FVIII) gene, suggesting that the light chain, covalently ligated to a co-expressed heavy chain can 
improve the secretion of spliced BDD-FVIII. However, its level of secretion was affected by inefficient secretion the heavy chain. 
Here, we studied the effect of a mutant heavy chain with L303E/F309S substitutions, which enhance FVIII secretion on the heavy 
chain itself and spliced FVIII when using a protein splicing-based split-delivery of a full-length FVIII gene. Eukaryotic vectors 
expressing Ssp DnaB intein-fused mutant heavy and light chains were transiently co-transfected into cultured COS-7 cells. A 
spliced FVIII protein was seen in co-transfected cells by Western blot analysis. The heavy chain was secreted by cells transfected 
with the mutant heavy chain gene alone at (39±11) ng/mL and this secretion increased to (123±13) ng/mL when cells were 
co-transfected with the light chain gene, which was greater than the secretion of wild-type heavy chain. The amount of spliced 
FVIII in the culture supernatant of co-transfected cells was (86±14) ng/mL, with an activity of (0.61±0.08) IU/mL, which was 
greater than that of wild-type FVIII co-transfected cells. Spliced FVIII and bioactivity were also detected in the combined culture 
supernatant of cells individually transfected with mutant heavy and light chain gene at a higher level than that of combined 
wild-type heavy and light chain transfections. This suggested that the heavy chain with improved secretion markedly increased the 
efficacy of protein splicing-based split delivery of the full-length FVIII gene using a dual-vector. These results encourage the 
transfer of this technology to an animal model using a dual-AAV vector. 
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Coagulation factor VIII (FVIII) is involved in the activation 
of the intrinsic coagulation pathway, functioning as a co- 
factor of active FIX to accelerate FX activation. FVIII de- 
fects cause hemophilia A, an X-linked bleeding disorder 
that accounts for the majority of all hemophilia patients [1]. 
In comparison to current treatment of mainly plasma-    
derived and recombinant FVIII protein replacement, which 
is expensive and has a risk of blood-borne virus infection, 
gene therapy has the potential to provide a cure for hemo- 
philia A [2]. However, because of inefficient secretion of  
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FVIII and the large FVIII gene, which is difficult to package 
in the promising adeno-associated virus (AAV) vectors, 
progress of hemophilia A gene therapy has been slow.  
FVIII binds to immunoglobulin-binding protein (BiP), an 
endoplasmic reticulum (ER) chaperone protein, during se-
cretion and the release of FVIII is dependent on a high con-
centration of intracellular ATP. L303E/F309S mutations in 
the A1 domain of the FVIII heavy chain improve its secre-
tion by reducing the affinity of FVIII for BiP [3,4]. As an 
alternative technology, dual-vector co-delivery of FVIII 
heavy and light chain genes can overcome the AAV capa- 
city constraints, but its main drawback is chain imbalance 
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due to the low secretion of the heavy chain relative to effi-
cient light chain secretion [5,6]. An intein is a protein se-
quence embedded in-frame within a precursor protein se-
quence that is excised during the maturation process of pro-
tein splicing, which is an analog of RNA splicing [7]. Pro-
tein splicing has been applied in protein engineering and 
other fields in recent years as a technical tool. We have re-
cently used a protein splicing-based dual-vector system for 
co-delivery of a B-domain-deleted FVIII (BDD-FVIII) gene 
and demonstrated that the co-expressed heavy and light 
chains can be spliced to form a complete BDD-FVIII, and 
that the light chain shows a cis-promoting function for the 
secretion of spliced BDD-FVIII [8,9]. Surprisingly, the secre-
tion of L303E/F309S BDD-FVIII heavy chain by itself was 
even lower than its wild-type form and BDD-FVIII [8]. In the 
current study, we utilized a protein splicing-based dual-vector 
to co-transfer the full-length FVIII gene with L303E/F309S 
mutations to investigate the secretion of the mutant heavy 
chain and spliced FVIII. The data showed an obviously im-
proved secretion of the mutant heavy chain by itself and 
spliced FVIII with an increased bioactivity. This provides an 
experimental basis for transferring dual-AAV vector 
co-delivery of full-length FVIII gene to animal models. 
1  Materials and methods 
1.1  Materials 
pXX-FVIII, containing a full-length human FVIII cDNA, 
was constructed and kindly provided by Dr. Xiao Xiao of 
Pittsburg University. The expression vectors for Ssp DnaB 
intein-infused FVIII heavy chain with F309S mutation, 
pCMV-HIn, for Ssp DnaB intein-infused FVIII light chain, 
pCMV-IcL and for full-length FVIII, pCMV-FVIII were 
previously constructed in our laboratory. COS-7 cells were 
obtained from the Chinese Academy of Sciences.  
The high fidelity DNA polymerase Pfu Turbo was ob-
tained from Stratagene (Santa Clara, CA, USA). The Gel 
Extraction kit, PCR purification kit and Spin Miniprep kit 
were obtained from Qiagen (Germany). The cell culture and 
transfection reagents were obtained from Invitrogen. The 
fetal bovine serum was from Hyclone (South Logan, UT, 
USA). The recombinant human factor VIII was from Bio- 
Chain (Hayward, CA, USA). The FVIII heavy chain-speci- 
fic monoclonal antibody, ESH5, light chain-specific mono- 
clonal antibody, ESH8, and the horseradish peroxidase 
(HRP)-conjugated ESH8, HRP-ESH8, were purchased from 
American Diagnostica (Stamford, CT, USA); HRP-conju- 
gated rabbit anti-human FVIII polyclonal antibody was 
purchased from Novus (Littleton, CO, USA); HRP-conju- 
gated sheep anti-rabbit secondary antibody and the ECL 
Plus Western blotting detection kit were obtained from Am- 
ersham Pharmacia Biotech (Piscataway, NJ, USA). Normal 
human reference plasma was obtained from George King 
Biomedical (Overland Park, KA, USA). A chromogenic kit 
for the determination of FVIII activity, COATEST SP FVIII 
was purchased from Chromogenix (Milan, Italy). 
1.2  Vector construction 
The intein-fused L303E/F309S heavy chain expression 
vector, pCMV-MHCIn, was constructed by introducing the 
L303E mutation into the FVIII heavy chain by inverse PCR 
using Pfu Turbo DNA polymerase, primers (5′-AGG- 
ACAGTTTCTACTGTTTTG-3′ and 5′-TCGTCCATCAA- 
GAGTGTTTG-3′) with pCMV-HIn, containing Ssp DnaB 
intein-fused F309S heavy chain, as a template followed by 
self-ligation of the PCR product. To construct the Ssp DnaB 
intein-fused wild-type heavy chain expression vector, 
pCMV-HCIn, inverse PCR was carried out using primers 
(5′-CTTGTCATATCTCTTCCCACCA-3′ and 5′-ACAGT- 
AGAAACTGTCCAAGGT-3′) with pCMV-HIn as template 
to convert the Glu330 codon to Leu followed by circulariza-
tion of the PCR product. For convenience, the plasmid 
pCMV-IcL, expressing Ssp DnaB intein-fused light chain 
constructed previously, was renamed as pCMV-IcLC. 
1.3  Cell culture and gene transfection 
COS-7 cells were maintained at 37°C in an atmosphere of 
5% CO2 and were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine 
serum. 24 h before transfection, cells were harvested using 
0.05% trypsin and plated onto a 6-well plate at 5×105 cells 
per well. When the cells were 90% confluent, they were 
co-transfected with the pCMV-MHCIn and pCMV-IcLC 
plasmids using Lipofectamine 2000 (Invitrogen) in accor-
dance with the manufacturer’s instructions. 6 μg of each 
plasmid was diluted in 250 μL of Opti-MEM and gently 
mixed with 20 μL of lipofectin in 250 μL of Opti-MEM for 
5 min at room temperature, followed by further 20 min in-
cubation at room temperature without shaking, before adding 
the complexes to the cells. As a control, cells were co-trans- 
fected with pCMV-HCIn and pCMV-IcLC. In addition, 
pcDNA3.1 and pCMV-FVIII were transfected into cells as a 
mock control and to express full-length FVIII, respectively. 
After incubation at 37°C in a CO2 incubator for 5 h, the 
culture media was changed to fresh Opti-MEM and the cells 
were incubated for another 48 h prior to testing transgene 
expression and protein trans-splicing. To observe protein 
splicing after secretion, cells were separately transfected 
with pCMV-MHCIn (or pCMV-HCIn) and pCMV-IcLC, 
then combined together followed by incubation for 24 h. 
The culture supernatants were collected for analysis. 
1.4  Western blot analysis for FVIII splicing 
For Western blot analysis, cells were lysed by repeated 
freeze-thawing, in liquid nitrogen and a water bath at 37°C. 
After protein quantification by the Bradford method, 12 μg 
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of total cellular proteins were resolved and separated by 
SDS-PAGE and transferred onto PVDF membrane by a 
semi-dry method. After blocking the membrane with 5% 
skimmed milk powder at room temperature for 2 h, it was 
incubated with a rabbit anti-human FVIII polyclonal anti-
body for 1 h at 37°C followed by HRP-conjugated secon-
dary antibody for 1 h at 37°C. Hybridization was visualized 
with the ECL Plus Western blotting detection system. 
1.5  Determination of secreted heavy and light chains 
and spliced FVIII 
The concentration of heavy and light chains in the culture 
supernatants was measured by heavy chain and light chain- 
specific ELISA, respectively, as described previously [8].  
A sandwich ELISA was performed to measure the con-
centration of the spliced full-length FVIII protein in the cul-
ture supernatant using chain-specific antibodies [10]. The 
FVIII heavy and light chain antibodies were used as capture 
and detection antibodies. NUNC Maxisorb 96-well plates 
were coated overnight at 4°C with 2 μg/mL FVIII heavy 
chain-specific monoclonal antibody ESH5. The plates were 
washed with phosphate-buffered saline (PBS)-0.05% Tween 
20 and then blocked with PBS-1% bovine serum albumin 
(BSA)-0.05% Tween 20 for 2 h at 37°C. 100 μL of standard 
recombinant FVIII dilutions in Opti-MEM, ranging in con-
centration from 10 to 300 ng/mL, and samples were added to 
wells, in triplicate. The plates were incubated for 1 h at 37°C 
and washed 3 times. 100 μL of HRP-conjugated light chain- 
specific antibody, HRP- ESH8, at a concentration of 2 μg/mL 
was added to each well and the plates were incubated for 1 h 
at 37°C. After a final wash, the substrate OPD was added and 
the plates were incubated for 30 min at 37°C. The reaction 
was terminated with 2 mol/L H2SO4, then the absorbance was 
read at 490 nm. A standard working curve was plotted based 
on the absorbance versus concentration of the diluted stan-
dards, and FVIII concentration in the supernatant was deter-
mined from the standard curve.  
1.6  Analysis of FVIII bioactivity of culture super-
natants 
The activity produced by FVIII in the supernatant was 
measured using the Coatest chromogenic method [11] in 
accordance with the manufacturer’s instructions. Normal 
human plasma was used as a standard with a defined FVIII 
activity of 1.0 IU/mL. A standard curve was generated from 
405 nm absorbance versus FVIII activities. The absorbance 
of samples was also read at 405 nm after serial reactions 
and the FVIII activity was deduced from the standard curve. 
1.7  Statistical analysis 
Data were expressed as mean ± SD. Significant differences 
among the groups were determined using Student’s paired t 
test and a value of P<0.05 was considered significant. 
2  Results 
2.1  Construction of intein-fused L303E/F309S FVIII 
heavy chain expression vector 
The structural domains of the full-length FVIII molecule are 
arranged as A1-A2-B-A3-C1-C2. Intein-fused wild-type 
heavy and light chain gene expression vectors, pCMV-HCIn 
and pCMV-IcLC were previously constructed by splitting 
the FVIII gene between Gly1238 and Ser1239 in the B do-
main into heavy and light chains, fusing Ssp DnaB intein N- 
and C-terminus, to them respectively, followed by insertion 
into the eukaryotic expression vector pcDNA3.1(+). The 
intein-fused L303E/F309S heavy chain expression vector 
pCMV-MHCIn was produced by introducing the L303E 
mutation into the intein-fused F309S heavy chain expres-
sion vector, pCMV-HIn, by PCR-directed mutagenesis. The 
structures of FVIII and of the fusion gene expression vec-
tors are illustrated in Figure 1. 
2.2  Intracellular splicing of FVIII protein 
Western blot of total cellular protein showed that the FVIII 
transgenic cells display an expressed FVIII protein of the 
expected size but that the mock transfected cells have no 
visible FVIII protein. The MHCIn and IcLC co-transfected 
cells displayed an obviously spliced FVIII (MHC-LC) con-
sistent in size with FVIII protein. They also displayed non- 
spliced protein precursors; intein-fused heavy and light 
chains (MHCIn and IcLC) were also detected, in a similar 
manner to that in cells separately transfected with MHCIn 
and IcLC genes. There may be two reasons for the non- 
complete splicing, one is the protein splicing reaction itself 
not entirely efficient and the other is the low efficiency of 
both intein-fused genes entering into the same target cell so 
that the expressed precursor proteins cannot meet intracel-
lularly for splicing (Figure 2). 
2.3  Improved heavy chain secretion and its role in 
promoting secretion of spliced FVIII 
Heavy chain-specific ELISA showed that the concentration 
of mutant heavy chain in the culture supernatant secreted by 
cells transfected with the MHCIn gene alone is (39±11) 
ng/mL, which was significantly higher than wild-type heavy 
chain secreted from HCIn transgenic cells (15±5 ng/mL), 
suggesting improvement of mutant heavy chain secretion. 
After co-transfection with the IcLC gene, secretion of the 
mutant heavy chain markedly increased to (123±13) ng/mL, 
which is composed of spliced FVIII and unspliced heavy 
chain, indicating the cis-promoting effect of the light chain 
on the secretion of mutant heavy chain. This was better than  
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Figure 1  Schematic illustration of FVIII and of the eukaryotic expression plasmid vectors. The structural domains of the full-length FVIII are arranged as 
A1-A2-B-A3-C1-C2. Intein-joined wild-type heavy chain and light chain expression vectors, pCMV-HCIn and pCMV-IcLC, were constructed by fusing N- 
and C-terminus (In, Ic) of Ssp DnaB intein to heavy and light chains, respectively. The intein-fused L303E/F309S heavy chain expression vector, 
pCMV-MHCIn, was made by PCR-directed mutagenesis. SS, signal sequence of FVIII. 
 
Figure 2  Intracellularly trans-spliced FVIII detected by Western blot. 
Total proteins in cell lysate were resolved by SDS-PAGE and probed with 
FVIII polyclone antibody. The MHCIn and IcLC co-transgenic cell shows 
a spliced FVIII protein (MHC-LC), and also non-completely spliced pre-
cursors, MHCIn and IcLC. 
the effect on the wild-type heavy chain, which was (82±16) 
ng/mL. The amount of heavy chain secreted by FVIII gene 
transfected control cells was (70±16) ng/mL, which was 
significantly less than co-transfected cells (Figure 3). Com-
pared to the improved secretion of the mutant FVIII heavy 
chain, we have recently reported that the secretion of mu-
tated BDD-FVIII heavy chain was even lower than that of 
BDD-FVIII itself [8]. 
As shown in Figure 4, a light chain-specific ELISA 
showed that the light chain secreted from MHCIn and IcLC 
co-transgenic cells was (168±23) ng/mL, which was 1.4 
times that of the heavy chain. The light chain secreted from 
HCIn and IcLC co-transgenic cells was (189±29) ng/mL, 
which was 2.3-fold higher than that of the heavy chain, sug-
gesting that mutant heavy chain and light chain co-transfected 
cells may alleviate the chain imbalance. The IcLC transgenic 
cells secreted (172±35) ng/mL of light chain, similar to levels 
of wild-type or mutant heavy chain plus light chain 
co-transfected cells, indicating that the heavy chain does not 
affect the secretion of light chain. These levels were signifi-
cantly higher than those of FVIII transgenic control cells 
(87±20 ng/mL) suggesting that secretion of light chain within 
the FVIII molecule was adversely affected by the inefficient 
heavy chain secretion (Figure 4). 
An intact FVIII molecule could be formed from the syn-
thesized intein-fusion heavy and light chains by protein 
splicing followed by secretion to the outside of the cell. The 
unspliced precursor peptides can also be secreted. The 
amount of spliced FVIII in the culture supernatant deter-
mined by sandwich ELISA demonstrated that MHCIn and 
IcLC in co-transgenic cells was (86±14) ng/mL, which was 
greater than that in HCIn and IcLC co-transgenic cells 
(57±8 ng/mL), and slightly higher than that in FVIII trans-
genic cells (75±12 ng/mL). This indicated that mutation of 
the heavy chain can improve protein splicing-based dual- 
vector co-delivery of the FVIII gene (Figure 5). A spliced 
FVIII was also detected at (23±5) ng/mL in the culture su-
pernatant of combined cells individually transfected with 
MHCIn and IcLC genes, which was at a higher level than 
that of combined HCIn and IcLC transgenic cells (13±4 
ng/mL) implying cellular mechanism-independent protein 
splicing and that the improved heavy chain secretion was 
beneficial to this kind of splicing.  
2.4  FVIII bioactivity of the culture supernatant  
The FVIII bioactivity of the culture supernatant, produced 
by spliced FVIII protein, was (0.61±0.08) IU/mL for 
MHCIn and IcLC co-transgenic cells, which was greater 
than that of HCIn and IcLC transgenic cells (0.42±0.07 
IU/mL). The bioactivity of culture supernatant of FVIII 
transgenic control cells was (0.48±0.11) IU/mL, which was 
lower than that of MHCIn and IcLC co-transgenic cells 
(Figure 6). This suggests that the mutant heavy chain could 
increase the efficacy of a dual-vector co-delivery of the  
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Figure 3  Heavy chain concentration in culture supernatants. **, P<0.05 
vs. HCIn transfection; ##, P<0.05 vs. HCIn and IcLC co-transfection. 
 
Figure 4  Light chain concentration in culture supernatants. *, P>0.05 vs. 
HCIn plus IcLC co-transfection, and IcLC transfection alone. 
 
Figure 5  Concentration of spliced FVIII protein in culture supernatants. 
**, P<0.05 vs. HCIn and IcLC co-transfection; *, P>0.05 vs. mixed HCIn 
and IcLC transfection. 
 
Figure 6  FVIII bioactivity of the culture supernatants. **, P<0.05 vs 
HCIn+IcLC co-transfection; *, P>0.05 vs. mixed HCIn and IcLC transfection. 
FVIII gene. FVIII bioactivity was also detected in culture 
supernatant of combined cells separately transfected with 
MHCIn and IcLC genes ((0.19±0.06) IU/mL), which was 
higher than that of combined HCIn and IcLC transgenic cells 
((0.12±0.03) IU/mL), indicating the contribution of cellular 
mechanism-independent spliced FVIII to bioactivity and that 
the mutant heavy chain could enhance this function. 
3  Discussion 
Dual-vector co-delivery of the FVIII gene, based on an un-
derstanding of physiological FVIII heterodimerization, is an 
alternative strategy to overcome the limited capacity of 
AAV vectors in hemophilia A gene therapy [5,6]. However, 
because of a dependence on functional heterodimerization, 
the transgenic efficacy relies on the efficiency of two vec-
tors entering the same target cells. An additional drawback 
is the inefficient secretion of heavy chain, which causes 
chain imbalance with light chain secreted at a rate 10- to 
100-fold higher than heavy chain. The excessively secreted 
light chain does not, therefore, associate with its counterpart 
heavy chain and does not contribute to bioactivity [5,6]. 
Furthermore, the heavy chain retained in the cell may de-
stabilize the cell and even induce apoptosis [12]. 
An interaction between FVIII and the endoplasmic re-
ticulum (ER) chaperone protein BiP is considered to be the 
main reason leading to inefficient FVIII secretion [3,13‒
15]. BiP is a peptide-dependent ATPase in the ER and binds 
unfolded, mutant or unassembled protein subunits within 
the ER. Release of FVIII bound to BiP during secretion 
requires high intracellular concentrations of ATP. Depletion 
of intracellular ATP by treatment with protonophore spe-
cifically inhibits secretion of FVIII, whereas secretion of 
FV, which has a similar structure to FVIII, is not affected 
[16,17]. Amino acid substitution experiments have shown 
that L303E and F309S point mutations in the A1 domain of 
the heavy chain reduce the affinity of FVIII with BiP lead-
ing to a 3-fold increase in FVIII secretion [4]. We have re-
cently used a dual-vector to transfer a F309S point mutated 
BDD-FVIII gene and demonstrated that the light chain 
could trans-promote secretion of the mutated heavy chain 
(although only at a level of approximately half that of 
BDD-FVIII) and that the mutated heavy chain by itself was 
secreted at even lower levels [8]. Therefore, it is difficult to 
improve the secretion of BDD-FVIII heavy chain by point 
mutations using dual-vector technology.  
In this study, the full-length FVIII gene with L303E/ 
F309S mutations in its heavy chain was used for split-de-
livery by a protein splicing-based dual-vector. The data 
showed an improved secretion of the mutant heavy chain by 
itself which increases substantially when co-transfected 
with the light chain gene with a ratio of heavy to light chain 
of 1:1.4 compared to 1:2.3 in the light and wild-type heavy 
chain co-transgenic cells. This indicated that the light chain 
has a more obvious enhancement on mutant heavy chain 
secretion, which is helpful to relieve the chain imbalance 
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problem. Also the amount of spliced FVIII secreted from 
the cells and its bioactivity were significantly higher com-
pared to that of wild-type FVIII gene co-transgenic cells. 
Therefore, the covalently ligated FVIII molecules catalyzed 
by protein splicing in the dual-vector co-delivery of the 
FVIII gene is similar to a single vector delivery of the 
full-length FVIII gene.  
The protein splicing catalyzed efficient, precise and 
seamless ligation of proteins, which makes intein a power-
ful technical tool in protein engineering and drug develop-
ment [18,19]. Recently, by von Willebrand factor (vWF) 
gene co-delivery, we demonstrated that as a FVIII carrier, 
the co-expressed vWF is able to promote the secretion of 
intein spliced BDD-FVIII [20]. This work provided valu-
able information for the use of protein splicing as a strategy 
for dual-AAV vector co-delivery of the mutant full-length 
FVIII gene in animal models to both circumvent the pack-
aging limitation of AAV and to improve the secretion of 
spliced FVIII. 
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